Introduction
PVL is usually associated with non multiresistant community-acquired MRSA. However, the epidemiology of PVL+-MRSA is changing.
Objectives
We describe the resistance patterns and molecular epidemiology of PVL+-MRSA isolates from 17 countries around the world.
Methods
Retrospective laboratory-based survey from 2008 to 2010. Participating countries (Australia, Brazil, Canada, China, Denmark, France, Germany, Greece, Hong Kong, India, Italy, Japan, Korea, Malaysia, Netherland, Poland, Switzerland) reported on susceptibility to 10 non-betalactam antibiotics and MLST and/or spa typing of PVL+ MRSA isolates. A selection of 49 isolates were analysed by MLVA.
Results
Overall, susceptibility data of 3236 was reported. The lowest susceptibility was observed for erythromycin in all regions (17.3% in the Americas and 60% both in Europe and Asia&Oceania). Vancomycin-intermediate isolates were reported from Hong Kong and The Netherlands. Multiresistance (3 or more non-beta-lactams) was reported from all regions. Isolates belonged to 8 clonal complexes. ST30 was reported worldwide, being the most frequent type in Brazil and Asia. ST8 was the most frequent in Canada. In Europe, ST80 and ST8 were both reported in the first place. Six major clusters were discriminated by this method, showing a certain geographic specificity and agreement with MLST.
Conclusion PVL+-MRSA remains frequently susceptible to nonbeta-lactam agents, with in vitro activity of vancomycin, rifampicin, cotrimoxazole and linezolid. However, multiresistant isolates were reported from all regions. Our results are in agreement with recent observations that suggest that USA300 and related clones are gradually replacing the European ST80 clone. It is imperative to continue monitoring susceptibility patterns and molecular epidemiology of MRSA to provide clinicians with the most up-to-date information. 
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